Summit Therapeutics (SUMM)

 

SUMM Share PerformanceMore

52 week high159.00 26/09/16
52 week low82.75 04/03/16
52 week change -3.00 (-2.11%)
4 week volume2,340,835 03/09/16

Media for (SUMM)

Latest NewsMore

Summit Therapeutics plc : Holding(s) in Company

Summit Therapeutics plc: Holding(s) in Company TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii Summit Therapeutics plc 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights X An acquisi...

Summit Received Rare Pediatric Disease Designation from US FDA for Ezutromid in Treatment of DMD

Summit Received Rare Pediatric Disease Designation from US FDA for Ezutromid in Treatment of DMD Summit Therapeutics plc ("Summit" or "the Company") SUMMIT RECEIVES RARE PEDIATRIC DISEASE DESIGNATION FROM US FDA FOR EZUTROMID IN TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY Oxford, UK, 27 September 2...

Summit Receives Fast Track Designation from US FDA for Ezutromid in the Treatment of DMD

Summit Receives Fast Track Designation from US FDA for Ezutromid in the Treatment of DMD Summit Therapeutics plc ("Summit" or "the Company") SUMMIT RECEIVES FAST TRACK DESIGNATION FROM US FDA FOR EZUTROMID IN THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY Oxford, UK, 26 September 2016 - Summit Ther...

Summit Therapeutics widens H1 loss

Summit Therapeutics has posted an H1 loss of $17.9m, from a loss of $13.5m a year ago. Most of the losses were due to resear...

Summit Therapeutics plc : Half-yearly report

Summit Therapeutics plc: Half-yearly report Summit Therapeutics plc ("Summit" or the "Company") SUMMIT THERAPEUTICS REPORTS FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED 31 JULY 2016 AND OPERATIONAL PROGRESS Conference call to be held 1:00pm BST / 8:00am EDT Oxford, UK, 8 September 2016 - Summit Therapeutics...

Summit Therapeutics to Present at 18th Annual Rodman & Renshaw Global Investment Conference

Summit Therapeutics to Present at 18th Annual Rodman & Renshaw Global Investment Conference SUMMIT THERAPEUTICS TO PRESENT AT 18 TH ANNUAL RODMAN & RENSHAW GLOBAL INVESTMENT CONFERENCE Oxford, UK, 7 September 2016 - Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development ...

Summit Therapeutics plc : Notice of Results

Summit Therapeutics plc: Notice of Results Summit Therapeutics plc ("Summit" or the "Company") SUMMIT THERAPEUTICS TO REPORT FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED 31 JULY 2016 ON 8 SEPTEMBER 2016 Oxford, UK, 5 September 2016 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and ...

Summit Reports Positive Phase 1 Data and Outlines Route to Market Strategy for DMD Candidate Ezutromid

Summit Reports Positive Phase 1 Data and Outlines Route to Market Strategy for DMD Candidate Ezutromid Summit Therapeutics plc ("Summit" or "the Company") SUMMIT REPORTS POSITIVE PHASE 1 NEW FORMULATION DATA AND OUTLINES ROUTE TO MARKET STRATEGY FOR DMD CANDIDATE EZUTROMID New formulation of ezutro...

Fundamental DataMore

EPS-41
Dividend yield0 %

Latest discussion posts More

  • Rabbit out of hat?

    Will Summit announce a DMD partnership in October and take Riddy C-dif into Phase 3 themselves with the collaboration monies? Just a thought.
    9-Sep-2016
    bobsson
  • Sad indictment

    A sad indictment of big pharma when Glyn commented in the webcast that no Riddy deal was likely in the near term and that Summit would have to raise money soon. He was hoping ...
    9-Sep-2016
    bobsson
  • Underwhelmed

    Interim results out, and look disappointing to me. Cash runs out end of January 2017, so will need to raise money by end of October. Cannot see any Riddy C-Dif deal before ...
    8-Sep-2016
    bobsson

Users' HoldingsMore

Users who hold Summit Therapeutics also hold..
RANGE RES.19%
LLOYDS GRP.19%
ROYAL BANK SCOT17%
TESCO13%
ROCKHOPPER13%

Codes & Symbols

ISINGB00BN40HZ01
SymbolsSUMM, LSE:SUMM, SUMM.L, SUMM:LN, LON:SUMM, XLON:SUMM